Updated on September 21, 2022
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, July 20, 2022 (HealthDay News) -- Hormone replacement therapy (HRT) for breast cancer survivors doesn't appear to increase the risk of cancer recurrence or death, Danish researchers report.
Although HRT has previously been linked to a raised risk of breast cancer's return, those earlier studies referred to oral HRT and not vaginal estrogen cream. The latest study, however, found no increase in the risk of recurrence or death for women getting either type of HRT.
"These findings should be reassuring that the use of HRT is not related to any major risks in the recurrence of breast cancer or risk of death for most women," said lead researcher Dr. Soren Cold, from the department of oncology at Odense University Hospital.
For women taking aromatase inhibitors to lower estrogen levels, there is a small risk of recurrence, but no increased risk of death, he noted.
Cold added that while the study indicates short-term use of HRT for breast cancer patients appears safe, long-term use may be problematic.
In any case, he advises patients to have a detailed discussion with their doctor about using HRT.
"It's something that you'll have to discuss with your doctor because like all other treatments, there are pros and cons," Cold said. "You cannot say it's prohibited, but you have to discuss it strongly with your doctor."
For the study, Cold and his colleagues collected data on nearly 8,500 women diagnosed with early-stage breast cancer between 1997 and 2004. These women received either no hormone treatment or five years of hormone therapy.
Among the women who didn't receive vaginal estrogen therapy or menopausal hormone therapy before a breast cancer diagnosis, 1,957 used vaginal estrogen therapy and 133 used menopausal hormone therapy after their diagnosis.
Over a median of nearly 10 years of follow-up, 16% had a recurrence of breast cancer. In all, 111 patients who had a recurrence had received vaginal estrogen therapy, 16 had received menopausal hormone therapy, and about 1,200 women did not receive either treatment.
The report was published July 20 in the Journal of the National Cancer Institute.
Despite these findings, Dr. Brittney Zimmerman, a medical breast oncologist at Northwell Health Cancer Institute in Lake Success, N.Y., believes breast cancer survivors need to be cautious when using HRT.
The side effects from estrogen deprivation after breast cancer affect many women and can be a major reason for discontinuing breast cancer treatments, such as tamoxifen and aromatase inhibitors, she said.
"As a medical oncologist, one of my main roles is to help patients manage symptoms of these medications to improve quality of life, and help patients remain on their breast cancer-directed therapies," Zimmerman said.
Many strategies are available to manage these side effects, including hormonal and non-hormonal treatments.
"In general, we avoid estrogen-based hormonal therapies for patients with a prior history of breast cancer based on results of prior studies, which show an increased risk of breast cancer recurrence," Zimmerman said.
This study provides an interesting new observation about the use of vaginal estrogen therapy in patients with a history of breast cancer, she said.
"The study found a slightly increased risk of breast cancer recurrence among patients who used vaginal estrogen therapy and were taking aromatase inhibitors," Zimmerman noted.
Earlier studies have shown that vaginal estrogen is generally safe in breast cancer survivors and had very low estrogen absorption into the body, she said.
"I would, however, recommend patients with vaginal symptoms such as vaginal dryness or burning try non-hormonal therapies before using vaginal estrogen therapy," Zimmerman said.
But "this decision should be made after discussion with the patient’s breast medical oncologist," she added.
While the new study suggests there is no increased risk of breast cancer recurrence with oral hormonal therapy, several earlier studies have suggested an increased risk, Zimmerman noted.
"I would encourage all patients to discuss the use of hormonal therapy for hot flashes with their medical oncologist and to limit use while further studies are in process," she said.
For more on HRT and breast cancer, head to the American Cancer Society.
SOURCES: Soren Cold, MD, department of oncology, Odense University Hospital, Odense, Denmark; Brittney Zimmerman, MD, medical breast oncologist, Northwell Health Cancer Institute, Lake Success, N.Y.; Journal of the National Cancer Institute, July 20, 2022
- Lumpectomy as Effective as Mastectomy for Young Women With ... ›
- Diabetes Drug Metformin Disappoints in New Breast Cancer ... ›
- Breast Cancer Over 70: How Much Treatment Is Enough ... ›
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.